Research programme: obesity therapy - Nanodesign

Drug Profile

Research programme: obesity therapy - Nanodesign

Alternative Names: Obesity therapy research programme - Nanodesign

Latest Information Update: 20 Nov 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nanodesign (CEASED); SignalGene [CEASED]
  • Class
  • Mechanism of Action ERRalpha estrogen-related receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 20 Nov 2002 Discontinued - Preclinical for Obesity in Canada (unspecified route)
  • 21 May 2001 This programme is available for licensing or co-development (
  • 16 Jan 2001 Preclinical development for Obesity in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top